Now showing items 1-10 of 12
Skin autofluorescence and all-cause mortality in stage 3 CKD.
BACKGROUND AND OBJECTIVES: Novel markers may help to improve risk prediction in CKD. One potential candidate is tissue advanced glycation end product accumulation, a marker of cumulative metabolic stress, which can be ...
Risk profile in chronic kidney disease stage 3: older versus younger patients.
BACKGROUND: The prevalence of chronic kidney disease (CKD) increases with age, but its significance in older patients is uncertain and is regarded by some as part of 'normal aging'. Moreover, subjects ≥75 years are often ...
Tissue advanced glycation end product deposition after kidney transplantation.
BACKGROUND: Tissue advanced glycation end products (AGEs) accumulate in chronic kidney disease (CKD) and are a measure of cumulative metabolic stress. Measurement of tissue AGEs by skin autofluorescence (SAF) correlates ...
The impact of vitamin D status on the relative increase in fibroblast growth factor 23 and parathyroid hormone in chronic kidney disease.
Fibroblast growth factor (FGF) 23 is an important regulator of phosphaturia. Its serum level was found to increase before that of parathyroid hormone (PTH) in early chronic kidney disease (CKD) in some but not all previous ...
What is the value of multidisciplinary care for chronic kidney disease?
In a Persepctive, Richard Fluck and Maarten Taal discuss the potential value of implementing multidisciplinary care programs for chronic kidney disease.
The burden of comorbidity in people with chronic kidney disease stage 3: a cohort study.
BACKGROUND: Multimorbidity is a growing concern for healthcare systems, with many countries experiencing demographic transition to older population profiles. Chronic kidney disease (CKD) is common but often considered in ...
Determinants of arterial stiffness in chronic kidney disease stage 3.
BACKGROUND: Early chronic kidney disease (CKD) is associated with increased cardiovascular (CV) risk but underlying mechanisms remain uncertain. Arterial stiffness (AS) is associated with increased CV risk in advanced CKD, ...
Chronic Kidney Disease in Primary Care: Outcomes after Five Years in a Prospective Cohort Study.
BACKGROUND: Chronic kidney disease (CKD) is commonly managed in primary care, but most guidelines have a secondary care perspective emphasizing the risk of end-stage kidney disease (ESKD) and need for renal replacement ...
Assessment of proteinuria in patients with chronic kidney disease stage 3: albuminuria and non-albumin proteinuria.
BACKGROUND AND OBJECTIVE: Proteinuria assessment is key in investigating chronic kidney disease (CKD) but uncertainty exists regarding optimal methods. Albuminuria, reflecting glomerular damage, is usually measured, but ...